Literature DB >> 11455583

Gene regulatory potential of 1alpha,25-dihydroxyvitamin D(3) analogues with two side chains.

Y Bury1, M Herdick, M R Uskokovic, C Carlberg.   

Abstract

The nuclear hormone 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) acts through the transcription factor vitamin D receptor (VDR) via combined contact with the retinoid X receptor (RXR), coactivator proteins, and specific DNA binding sites (VDREs). Ligand-mediated conformational changes of the VDR are the core of the molecular switch of nuclear 1alpha,25(OH)(2)D(3) signalling. Studying the interaction of 1alpha,25(OH)(2)D(3) analogues with this molecular switch should allow the characterization of their potential selective biological profile. A 1alpha,25(OH)(2)D(3) analogue with two side chains (Ro27-2310 or Gemini) was found to stabilize functional VDR conformations and VDR-RXR heterodimers on a VDRE with a slightly lower sensitivity than the natural hormone. A 19-nor derivative of Gemini (Ro27-5646) showed similar sensitivity whereas 5,6-trans (Ro27-6462) 3-epi (Ro27-5840) and 1alpha-fluoro (Ro27-3752) derivatives were equal to each other, but approximately 30-times less sensitive than Gemini. A des-C,D derivative of Gemini (Ro28-1909) showed only residual activity at maximal concentrations. In contrast to 1alpha,25(OH)(2)D(3), Gemini and its derivatives showed a differential preference in stabilizing VDR conformations which was found to be modulated by DNA coactivator and corepressor proteins. An analysis of the gene regulatory potential of the VDR agonists in cellular reporter gene systems demonstrated the same ranking as in the in vitro systems, but Gemini and its 19-nor derivative were found to be more sensitive than 1alpha,25(OH)(2)D(3) which indicates that the natural hormone is selectively metabolized. This study used straightforward methods for the in vitro and ex vivo evaluation of the gene regulatory potential of 1alpha,25(OH)(2)D(3) analogues. Gemini was highlighted as an interesting drug candidate which could not be optimized through obvious chemical modifications in its A-ring. J. Cell. Biochem. Suppl. 36: 179-190, 2001. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455583     DOI: 10.1002/jcb.1082

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  4 in total

1.  Structure-function study of gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097.

Authors:  Tiphaine Huet; Hubert Maehr; Hong Jin Lee; Milan R Uskokovic; Nanjoo Suh; Dino Moras; Natacha Rochel
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

2.  Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Authors:  Ayelet Shabtay; Hagar Sharabani; Zeev Barvish; Michael Kafka; Doron Amichay; Joseph Levy; Yoav Sharoni; Milan R Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Oncology       Date:  2008-10-14       Impact factor: 2.935

3.  Calcitriol derivatives with two different side-chains at C-20. Part 4: further chain modifications that alter VDR-dependent monocytic differentiation potency in human leukemia cells.

Authors:  Edward Garay; Pawel Jankowski; Paulo Lizano; Stanislaw Marczak; Hubert Maehr; Luciano Adorini; Milan R Uskokovic; George P Studzinski
Journal:  Bioorg Med Chem       Date:  2007-04-25       Impact factor: 3.641

4.  Cyclical regulation of the insulin-like growth factor binding protein 3 gene in response to 1alpha,25-dihydroxyvitamin D3.

Authors:  Marjo Malinen; Jussi Ryynänen; Merja Heinäniemi; Sami Väisänen; Carsten Carlberg
Journal:  Nucleic Acids Res       Date:  2010-09-19       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.